Condensed Interim Financial Statements

For the six months ended August 31, 2022 and 2021

(Expressed in Canadian dollars)

(Unaudited - Prepared by Management)

# NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM FINANCIAL STATEMENTS

In accordance with National Instrument 51-102 Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of these condensed interim financial statements, they must be accompanied by a notice indicating that the condensed interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of the Company for the six months ended August 31, 2022 have been prepared by and are the responsibility of the Company's management, and have not been reviewed by the Company's auditors.

Condensed Interim Statements of Financial Position

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

(Orladdited – Frepared by Management)	August 31, 2022 \$	February 28, 2022 \$
Assets		
Current assets		
Cash and cash equivalents Prepaid expenses	272,362 10,022	1,296,097 20,137
Total current assets	282,384	1,316,234
Non-current assets		
Investments (Note 4)	1,484,112	779,553
Total assets	1,766,496	2,095,787
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities (Notes 5 and 7 Loans payable (Note 6)	1,143,492 235,000	1,119,708 235,000
Total liabilities	1,378,492	1,354,708
Shareholders' equity		
Share capital (Note 8) Share subscriptions receivable (Note 14) Warrant reserve Share-based payment reserve Equity component of convertible debt Deficit	7,041,028 (50,000) 867,262 1,068,798 176,251 (8,715,335)	7,041,028 (50,000) 867,262 1,068,798 176,251 (8,362,260)
Total shareholders' equity	388,004	741,079
Total liabilities and shareholders' equity	1,766,496	2,095,787
Nature of operations and continuance of business (Note 1 Commitment (Note 13) Subsequent event (Note 14)	)	
Approved and authorized for issuance by the Board of Dir	ectors on October 24, 2022:	
/s/ "Arif Merali"	/s/ "Ken Ralfs"	
Arif Merali, Director	Ken Ralfs, Director	

(The accompanying notes are an integral part of these condensed interim financial statements)

Condensed Interim Statements of Operations and Comprehensive Loss

(Expressed in Canadian dollars)
(Unaudited – Prepared by Management)

(Chaddica Trepared by Management)	For the three months ended August 31,			months ended ust 31,
	2022 \$	2021 \$	2022 \$	2021 \$
Investment income				
Realized gain on investments Unrealized gain (loss) on investments	- (69,780)	380 873,220	- (155,155)	380 923,220
Total investment income (loss)	(69,780)	873,600	(155,155)	923,600
Operating expenses				
Consulting fees (Note 7) General and administrative Marketing Professional fees (recovery) Share-based payments	74,357 606 - 2,566	294,952 6,376 119,325 (20,217)	152,715 2,590 - 6,354 -	300,452 9,849 119,325 6,132 240,000
Transfer agent and filing fees  Total operating expenses	6,932 84,461	16,943 417,379	9,452 171,111	22,585 698,343
Income (loss) before other expenses	(154,241)	456,221	(326,266)	225,257
Other expense				
Interest expense	(11,147)	(11,284)	(26,809)	(26,413)
Total other expenses	(11,147)	(11,284)	(26,809)	(26,413)
Net income (loss) for the period	(165,388)	444,937	(353,075)	198,844
Income (loss) per share, basic and diluted	0.00	0.00	0.00	0.00
Weighted average common shares outstanding	105,256,659	102,276,659	105,256,659	97,132,221

Condensed Interim Statements of Changes in Shareholders' Equity (Deficit) (Expressed in Canadian dollars)

(unaudited – Prepared by Management)

Tunadanea - Toparea ey mana	Share capital		Share		Equity Share-based component of payment convertible			Total shareholders' equity
	Number of shares	Amount \$	receivable \$	reserve \$	reserve \$	debt \$	Deficit \$	(deficit) \$
Balance, February 28, 2021	79,115,994	4,134,052	(15,000)	993,420	546,832	176,251	(7,157,009)	(1,321,454)
Private placement Share issuance costs Fair value of agent's warrants Exercise of share purchase	10,305,667 - -	824,453 (31,848) (27,500)	(50,000) - -	721,397 27,500	- - -	- - -	- - -	1,495,850 (31,848) –
warrants Share subscriptions received Exercise of stock options Share-based payment	13,234,998 - 2,100,000 -	1,626,860 - 252,000 -	15,000 –	(632,461) - -	- (126,000) 240,000	_ - _	- - -	994,399 15,000 126,000 240,000
Net income for the period	_	_	_	_	_	_	198,844	198,844
Balance, August 31, 2021	104,756,659	6,778,017	(50,000)	1,109,856	660,832	176,251	(6,958,165)	1,716,791
Balance, February 28, 2022	105,256,659	7,041,028	(50,000)	867,262	1,068,798	176,251	(8,362,260)	741,079
Net loss for the period	-	_	-	_	_	_	(353,075)	(353,075)
Balance, August 31, 2022	105,256,659	7,041,028	(50,000)	867,262	1,068,798	176,251	(8,715,335)	388,004

Condensed Interim Statements of Cash Flows

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

Conductive Tropared by Management)	For the six months ended August 31,	
	2022 \$	2021 \$
Operating activities:		
Net (loss) income for the period	(353,075)	198,844
Items not involving cash: Interest charges Share-based payments Loss (Gain) on fair value of marketable securities Realized gain on sale of marketable securities Changes in non-cash operating working capital: Amounts receivable Prepaid expenses	27,796 - 155,155 - - 10,115	26,413 240,000 (923,220) (380) (6,337) (68,224)
Accounts payable and accrued liabilities  Net cash used in operating activities	(4,012) (164,021)	(40,557) (573,461)
Investing activities  Marketable securities  Proceeds on sale of marketable securities	(859,714)	(1,432,930) 3,130
Net cash used in investing activities	(859,714)	(1,429,800)
Financing activities Loan payable (repaid) Proceeds from shares issued and share subscriptions received Share issuance costs	- - -	(150,000) 2,631,249 (31,848)
Net cash provided by financing activities	-	2,449,401
Change in cash and cash equivalents	(1,023,735)	446,140
Cash and cash equivalents, beginning of period	1,296,097	128,421
Cash and cash equivalents, end of period	272,362	574,561
Cash and cash equivalents consist of: Cash in bank Cash in legal trust account Cash in brokerage account	256,831 4,180 11,351	568,732 3,280 2,549
Total cash and cash equivalents	272,362	574,561
Cash paid for interest during the period Cash paid for income taxes during the period Non-cash investing and financing activities:	- -	- -
Fair value transferred on exercise of warrants and stock options Fair value of warrants issued as part of a private placement Fair value of agent's warrants issued	- - -	758,461 721,397 27,500

(The accompanying notes are an integral part of these condensed interim financial statements)

Notes to the Condensed Interim Financial Statements Period ended August 31, 2022 (Expressed in Canadian dollars) (Unaudited – Prepared by Management)

#### 1. Nature of Operations and Continuance of Business

Vinergy Capital Inc. (the "Company") was incorporated as Vanguard Investments Corp. on March 20, 2001, under the provisions of the Alberta Business Corporations Act. On May 10, 2011, the Company changed its name to Vinergy Resources Ltd. and continued the Company's registered jurisdiction from Alberta to British Columbia. On July 9, 2019, the Company changed its name to Vinergy Cannabis Capital Inc. On March 9, 2021, the Company changed its name to Vinergy Capital Inc. The Company's head office is located at Suite 1000, 409 Granville Street, Vancouver, BC, V6C 1T2 and its shares are listed on the Canadian Securities Exchange ("CSE") under the symbol "VIN". During the year ended February 29, 2020, the Company became an investment issuer.

The Company's business may be affected by changes in political and market conditions, such as interest rates, availability of credit, inflation rates, changes in laws, and national and international circumstances. Recent geopolitical events, including, the outbreaks of the coronavirus (COVID-19) pandemic, relations between NATO and Russian Federation regarding the situation in Ukraine, and potential economic global challenges such as the risk of the higher inflation and energy crises, may create further uncertainty and risk with respect to the prospects of the Company's business.

These condensed interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. During the period ended August 31, 2022, the Company did not generate any revenues and incurred negative cash flow from operations. As at August 31, 2022, the Company has a working capital deficit of \$1,096,108 (February 28, 2022 - \$38,474) and an accumulated deficit of \$8,715,335 (February 28, 2022 - \$8,362,260) since inception and expects to incur further losses in the development of its business. The Company is also in default for certain loans payable. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. Management is of the opinion that with its current cash and other funds that may be obtained from external financing that it has sufficient working capital to meet the Company's liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These condensed interim financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.

#### 2. Basis of Preparation

These condensed interim financial statements, including comparatives, have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), Interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC") and in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting.

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The assessment of the Company's ability to continue as a going concern (note 1) requires significant judgment. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

Notes to the Condensed Interim Financial Statements Period ended August 31, 2022 (Expressed in Canadian dollars) (Unaudited – Prepared by Management)

## 3. Significant Accounting Policies

The preparation of financial data is based on accounting principles and practices consistent with those used in the preparation of the audited financial statements as at February 28, 2022. The accompanying unaudited condensed interim financial statements should be read in conjunction with the Company's audited financial statements for the year ended February 28, 2022.

#### 4. Investments

Details of the Company's investments are as follows:

	Number of Shares held	Cost \$	Fair value as at August 31, 2022 \$
Public companies:			
Bitcoin Well Inc.	2,000,000	500,000	110,000
Nurosene Health Inc.	151,000	113,394	48,320
Prospera Energy Inc.	2,000,000	148,950	130,000
Skylight Health Group Inc.	400,000	356,780	248,000
Southern Energy Corp	200,000	120,955	202,000
Trillion Energy International Inc.	500,000	155,000	200,000
Private companies:			
CWE European Holdings Inc.	1,250,000	150,000	150,000
First Person Ltd.	50,000	175,000	316,925
Share purchase warrants	=	_	78,867
Total	6,551,000	1,720,079	1,484,112

	Number of Shares held	Cost \$	Fair value as at February 28, 2022 \$
Public companies: Bitcoin Well Inc. Nurosene Health Inc.	2,000,000 53,500	500,000 35,365	260,000 36,380
Private companies: CWE European Holdings Inc. First Person Ltd.	1,250,000 500,000	150,000 175,000	150,000 316,925
Share purchase warrants	_	_	16,248
Total	3,803,500	860,365	779,553

Notes to the Condensed Interim Financial Statements Period ended August 31, 2022 (Expressed in Canadian dollars) (Unaudited – Prepared by Management)

## 5. Accounts Payable and Accrued Liabilities

	August 31, 2022 \$	February 28, 2022 \$
Trade accounts payable	747,684	743,350
Accrued liabilities	6,976	15,322
Accrued interest payable (Note 6)	388,832	361,036
	1,143,492	1,119,708

#### 6. Loans Payable

- (a) On January 15, 2010, the Company issued a \$215,000 convertible debenture which bears interest at 10% per annum, is unsecured, and was due on January 16, 2015. The debenture was convertible into shares of the Company at a conversion price of \$0.05 per share at any time at the option of the holder prior to the due date. The Company's convertible debenture matured on January 16, 2015 and the Company continues to accrue interest at the rate of 10% per annum.
  - The fair value of the equity component was determined to be \$176,251 which was recorded as equity and an equivalent discount on the convertible debenture. The accretion of the discount was recognized over the term of the debenture. As at August 31, 2022, the carrying value of the convertible debenture is \$215,000 (February 28, 2022 \$215,000) and accounts payable and accrued liabilities includes \$250,814 (February 28, 2022 \$239,975) in interest with respect to these convertible debentures.
- (b) As at August 31, 2022, the Company owed \$20,000 (February 28, 2022 \$20,000) to a non-related party. The amount owing is unsecured, bears interest at 20% per annum compounded monthly, and is due on demand. As at August 31, 2022, the Company has incurred interest on this loan of \$112,105 (February 28, 2022 \$95,147), which is included in accounts payable and accrued liabilities.
- (c) On August 12, 2020, the Company issued a promissory note agreement for proceeds of \$96,000 to a non-related party. The promissory note is unsecured, bears interest at 20% per annum, and was due on December 31, 2021. On September 17, 2021, the Company repaid the loan principal balance of \$96,000. As at August 31, 2022, the Company has incurred interest on this promissory note of \$21,146 (February 28, 2022 \$21,146) to the non-related party which is included in accounts payable and accrued liabilities.
- (d) On July 2, 2019, the Company entered into a loan agreement with ESG Global Impact Capital Inc. ("ESG") for \$250,000. The loan was unsecured, bears interest at 10% per annum and due on July 31, 2020. As at December 21, 2020, the Company entered into a debt settlement agreement with ESG to settle \$100,000 of the principal. The Company agreed to issue 2,000,000 units at a price of \$0.05 per unit. Each unit consisted of one common share and one share purchase warrant exercisable at \$0.06 per share expiring on December 21, 2021. As at February 28, 2021, the Company had incurred interest on this promissory note of \$39,206 to the non-related party which is included in accounts payable and accrued liabilities. On April 14, 2021, the Company repaid the debt of \$150,000 plus interest of \$36,450. There is a remaining interest payable of \$4,767 as at August 31, 2022 and February 28, 2022.

Notes to the Condensed Interim Financial Statements Period ended August 31, 2022 (Expressed in Canadian dollars) (Unaudited – Prepared by Management)

#### 7. Related Party Transactions

- (a) As at August 31, 2022, the Company owed \$21,000 (February 28, 2022 \$21,000) to a company controlled by the Chief Financial Officer of the Company which is included in accounts payable and accrued liabilities. During the six months ended August 31, 2022, the Company incurred \$31,500 (2021 - \$31,750) in consulting fees to a company controlled by the Chief Financial Officer of the Company.
- (b) During the six months ended August 31, 2022, the Company incurred \$46,000 (2021 \$9,000) in consulting fees to the Chief Executive Officer ("CEO") of the Company.
- (c) During the six months ended August 31, 2022, the Company incurred \$66,000 (2021 \$55,000) in consulting fees to a director of the Company.

## 8. Share Capital

Authorized: Unlimited number of common shares without par value

There were no shares issued during the six months ended August 31, 2022.

Shares transactions during the year ended February 28, 2022:

- (a) On April 14, 2021, the Company completed a private placement and issued 10,305,667 units at \$0.15 per unit for gross proceeds of \$1,545,850 of which \$50,000 is included share subscriptions receivable as at February 28, 2022 (refer to Note 14). Each unit consisted of one common share and one-half of a share purchase warrant exercisable at a price of \$0.25 per common share expiring April 14, 2023. The fair value of warrants issued was determined to have a fair value of \$497,002 and was recorded in warrant reserve. The fair value of the warrants issued were estimated using the Black-Scholes option pricing model with the following assumptions: risk-free interest rate of 0.26%, dividend yield of 0%, volatility of 274%, and expected life of two years The Company paid a finder's fee of \$31,849 and issued 262,320 agent's warrants. Each agent's warrant is exercisable at a price of \$0.15 per common share on or before October 14, 2021 and at a price of \$0.20 per common share thereafter until April 14, 2022. The Company fair valued the agent's warrants at \$44,571 using the Black-Scholes option pricing model with the following assumptions: risk-free interest rate of 0.17%, dividend yield of 0%, volatility of 234% and expected life of one year.
- (b) During the year ended February 28, 2022, the Company issued 13,734,998 common shares for proceeds of \$1,019,400 pursuant to the exercise of share purchase warrants. The fair value of \$667,731 was transferred from warrant reserves to share capital upon exercise of the share purchase warrants.
- (c) During the year ended February 28, 2022, the Company issued 2,100,000 common shares for proceeds of \$126,000 pursuant to the exercise of stock options. The fair value of \$121,417 was transferred from share-based payment reserve to share capital upon exercise of the stock options.

Notes to the Condensed Interim Financial Statements Period ended August 31, 2022 (Expressed in Canadian dollars) (Unaudited – Prepared by Management)

#### 9. Share Purchase Warrants

The following table summarizes the continuity of share purchase warrants:

	Number of Warrants	Weighted average exercise price
Balance, February 28, 2021	36,308,330	0.06
Issued Exercised Expired	5,415,154 (13,734,998) (3,773,332)	0.25 0.07 0.07
Balance, February 28, 2022	24,215,154	0.10
Expired	(262,320)	0.25
Balance, August 31, 2022	23,952,834	0.09

During the period ended August 31, 2022, the Company extended the expiry date of 18,800,000 share purchase warrants from May 23, 2022, to May 23, 2023.

As at August 31, 2022, the Company had the following share purchase warrants outstanding:

Number of	Exercise		
warrants	price		
outstanding	\$	Expiry date	
18,800,000	0.05	May 23, 2023	
5,152,834	0.25	April 14, 2023	
23,952,834			

## 10. Stock Options

The Company has established a stock option plan for directors, employees and consultants which is administered by the board of directors with full and final authority with respect to the granting of all options. The exercise prices shall be determined by the board, but shall, in no event, be less than the closing market price of the Company's shares on the grant date, less the maximum discount permitted under the TSX Venture Exchange's policies. The number of common shares issuable under the plan may not exceed 10% of the issued and outstanding common shares. In addition, the number of common shares which may be reserved for issuance to any one individual may not exceed 5% of the issued common shares on a yearly basis. Options may be exercisable for a maximum of ten years from the date of grant.

Notes to the Condensed Interim Financial Statements Period ended August 31, 2022 (Expressed in Canadian dollars) (Unaudited – Prepared by Management)

## 10. Stock Options (continued)

The following table summarizes the continuity of the Company's stock options:

	Number of options	Weighted average exercise price \$
Outstanding, February 28, 2021	6,500,000	0.06
Granted Exercised Expired	4,800,000 (2,100,000) (2,000,000)	0.18 0.06 0.06
Outstanding, February 28, 2022	7,200,000	0.14
Expired	(2,800,000)	0.26
Outstanding, August 31, 2022	4,400,000	0.06

Additional information regarding stock options outstanding as at August 31, 2022 is as follows:

_	Outstanding and exercisable			
		Weighted		
Range of		average	Weighted	
exercise		remaining	average	
prices	prices Number of		exercise price	
\$	options	(years)	\$	
0.06	2,400,000	0.31	0.06	
0.09	250,000	2.05	0.09	
0.06	1,750,000	2.43	0.06	
	4,400,000	1.25	0.06	

#### 11. Financial Instruments and Risk Management

#### (a) Fair Values

Assets and liabilities measured at fair value on a recurring basis were presented on the Company's statement of financial position as at August 31, 2022 and February 28, 2022 as follows:

	Fair value measurements using			
	Quoted prices in	Significant		
	active markets	other	Significant	
	for identical	observable	unobservable	Balance,
	instruments	inputs	inputs	August 31,
	(Level 1)	(Level 2)	(Level 3)	2022
	\$	\$	\$	\$
Investments	938,320	78,867	466,925	1,484,112

Notes to the Condensed Interim Financial Statements Period ended August 31, 2022 (Expressed in Canadian dollars) (Unaudited – Prepared by Management)

#### 11. Financial Instruments and Risk Management (continued)

### (a) Fair Values (continued)

,	Fair value measurements using			
	Quoted prices in active markets	Significant other	Cignificant	
	for identical		Significant unobservable	Balance,
	instruments	inputs	inputs	February 28,
	(Level 1) \$	(Level 2) \$	(Level 3) \$	2022 \$
Investments	296,380	16,248	466,925	779,553

The fair values of other financial instruments, which include cash and cash equivalents, advance receivable, accounts payable and accrued liabilities, and loans payable, approximate their carrying values due to the relatively short-term maturity of these instruments.

#### (b) Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit loss by placing its cash and cash equivalents with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure.

#### (c) Foreign Exchange Rate Risk

Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is not exposed to any significant foreign exchange rate risk.

#### (d) Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk as it does not have any liabilities with variable rates.

#### (e) Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company currently settles its financial obligations out of cash. The ability to do this relies on the Company raising equity financing in a timely manner and by maintaining sufficient cash in excess of anticipated needs.

Notes to the Condensed Interim Financial Statements Period ended August 31, 2022 (Expressed in Canadian dollars) (Unaudited – Prepared by Management)

#### 12. Capital Management

The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of cash and cash equivalents and equity comprised of issued share capital, share subscriptions receivable, warrant reserve, share-based payments reserve, and equity component of convertible debt.

The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board of Directors, will balance its overall capital structure through new share issues or by undertaking other activities as deemed appropriate under the specific circumstances.

The Company is not subject to externally imposed capital requirements and the Company's overall strategy with respect to capital risk management remained unchanged from the year ended February 28, 2022.

#### 13. Commitment

On April 1, 2021, the Company entered into a consulting agreement with a director of the Company who later became the CEO, which is effective until December 31, 2024. Pursuant to the agreement, the Company agreed to pay \$120,000 per annum and two types of bonuses. There is an annual bonus of up to 8% of the base salary payable quarterly based on performance reviews by the Board of Directors and another bonus based on portfolio performance which does not exceed 10%.

#### 14. Subsequent Event

Subsequent to August 31, 2022, the Company returned and cancelled 333,334 common shares to treasury due to the non-receipt of the \$50,000 in share subscriptions receivable. The Company also cancelled 166,667 share purchase warrants.